Pharma vets with Genentech connection band together to launch new immunotherapy startup, though details are scant
On Thursday, three researchers announced they had started up a new immunotherapy biotech called LTZ Therapeutics, short for “Lift To Zenith,” and launched with a modest raise they’re calling a “pre-Series A.” In total, it’s a $17 million round, led by K2 Venture Partners and assisted by Qiming Venture Partners and Tigermed.
There are few details so far, but the company is making an initial impression thanks to a direct connection to Genentech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.